About this entry
ODYSIGHT is a digital medical device from Tilak Healthcare used for medical telemonitoring of visual acuity at home. France granted it early digital coverage (PECAN) under article L. 162-1-23 of the Social Security Code by arrêté of 27 November 2025, published in the Journal officiel. Coverage runs for one year from the order taking effect (13 days after publication). It is indicated for adults with chronic maculopathy complicated by, or at risk of, choroidal neovascularization or macular edema, with corrected binocular acuity of at least 3/10. The exploitant monthly forfait is EUR 50 TTC per patient. This page is not legal or reimbursement advice; confirm the current order on Légifrance.
- App
- ODYSIGHT
- Maker
- Tilak Healthcare
- Country
- France
- Program
- PECAN
- Status
- PECAN active
- Indication detail
- CIM-11 Class 09, posterior segment / retinal disease; eligible adults with corrected binocular acuity ≥3/10 needing or at risk of needing intravitreal injection or laser
- Coverage effective
- 2025-12-11
- PECAN coverage ends
- 2026-12-11
- Public price
- EUR 50.00 per 30-day unit
- Arrêté date
- 2025-11-27
- Journal officiel publication
- 2025-11-28
Not legal or reimbursement advice. Confirm the current entry with the official source.